Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults


  • The P-IV VERIFY study involves assessing of Galvus (50mg, bid) + Metformin (1000–2000 mg, qd) vs SOC monothx. approach with metformin initiated in treatment naïve patients (n=2001) in a ratio (1:1), recently diagnosed with T2DM across 34 countries for 5yrs.
  • The P-IV VERIFY study resulted in meeting its 1EPs i.e, 49% reduction in the risk for time to initial treatment failure as defined as HbA1c >=7%, showed a lower frequency of secondary failure with consistent safety & tolerability profile
  • Vildagliptin/Metformin dual regimen is the combination of two anti-diabetic agents with complementary mechanism and is the single pill dual therapy of DPP-4 inhibitor with metformin to be approved in Japan & Europe

Click here to­ read full press release/ article | Ref: Novartis | Image: Pharma News